NCT01747551View on ClinicalTrials.gov

FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

November 29, 2016

Study Completion Date

July 26, 2017

Conditions
Esophageal CancerGastric Cancer
Interventions
DRUG

Oxaliplatin

DRUG

Leucovorin

DRUG

Fluorouracil

DRUG

Ziv-aflibercept

Trial Locations (2)

02214

Massachusetts General Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER

NCT01747551 - FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer | Biotech Hunter | Biotech Hunter